Cell and Gene Outsourcing
-
What Does The Catalent Acquisition By Novo Holdings Mean For The Biopharma Industry?
2/12/2024
Novo Holdings, the parent company to Novo Nordisk, announced a deal last week to acquire Catalent, the global CDMO, at a value of $16.5bn. In the same breath, Novo Holdings announced they will sell three sites directly to Novo Nordisk, implying that the rest of the assets of the company will continue to operate as a stand-alone CDMO. This article unpacks the acquisition, discussing questions such as “what does it mean for customers?” and “does this deal reshape the CDMO market?”
-
Adopting Modular, Semi-Automated Approaches To Optimize CGT Development
2/7/2024
There are a number of technology solutions that, when applied to a cell and gene therapy workflow, can streamline development and improve workflow integration.
-
Exploring The Landscape, Modalities, And Logistics Of CGTs
1/31/2024
Explore the latest market trends and the nuances of various cell and gene therapy modalities, along with the logistical considerations necessary to safeguard product quality and safety.
-
The Ins And Outs Of In-House Manufacturing: Building A Cell & Gene Production Facility
1/30/2024
Deciding whether to bring manufacturing in-house or outsource it to a partner can be a daunting decision, particularly as market forces continue to put pressure on small biotechs.
-
Reducing Risk For Commercial Manufacturing Of Cell And Gene Therapies
1/25/2024
For any biotherapeutic in development today, a critical element in achieving commercialization is reducing manufacturing risk.
-
Shaping A Digitally Enabled Commercialization Road Map For Your Cell/Gene Therapy Company
1/25/2024
For cell and gene therapy companies, it is critical for commercial, marketing, and digital leaders to understand key business decisions that shape the digital backbone of your commercialization road map.
-
Ensure Data Quality Through Mass Balance Calculations
1/24/2024
Improve your cell line performance and process optimization using a cloud bioreactor that enable accurate, real-time monitoring of the whole cell culture fluid mass.
-
How To Speed Up Time To Market With CMC Knowledge Management
1/24/2024
Poor knowledge management delays regulatory approval and, thus, market access. Here's the first in a series examining the complexity of knowledge management for CMC and across the value stream.
-
A Deeper Dive On Mitigating Financial Risk Before Selecting A Vendor
1/23/2024
In part two of this webinar series, presenters focus on avoiding potential risks such as unexpected budget changes and unplanned change orders that could jeopardize the success of a clinical trial.
-
cGMP Assurance of Supply Services
1/23/2024
Explore the stocking solution offered to a mid-sized CDMO in need of a high volume of safety stock inventory to support their customer portfolio growth.